Nintx (Next Innovative Therapeutics) originated in Brazil as a startup with innovation as core business, heavily based on advanced technologies to develop the next generation of therapies.
Nintx relies on intra and interspecies biology (Plants/Microorganisms). The derived natural products/metabolites from these organisms and interactions thereof can lead into novel therapies for human use through the application of advanced analytical and screening techniques, metagenomics and metabolomics, computational methodologies, and medicinal chemistry. Nintx is agile, open, collaborative, technology driven and nature inspired, following ESG guiding principles, to bring future treatments today.
Nintx was founded by two PhD scientists, Dr. Miller Freitas and Dr. Cristiano Guimarães. In addition to the proven academic track record, they held prominent leadership R&D positions at the forefront of innovation in the pharmaceutical industry, both in Brazil and the US, leading innovative programs that are currently under global development. Their combined scientific knowledge and experience are crucial for both the discovery and development stages, as well as the registration of novel therapies.
Chemical Engineer, M.Sc./PhD in Computational/Organic Chemistry from the Federal University of Rio de Janeiro, followed by a 4-year post-doctorate in Computational/ Medicinal Chemistry at Yale University. Nine years of experience as a Scientist (Drug Design) and project leader in big pharma (Amgen and Pfizer), followed by seven years of experience in a top Brazilian pharma (Aché), responsible for Scientific/Regulatory/IP strategy and preclinical packages, a pipeline of about 15 small molecule/natural products programs in discovery and early development stages, a Synthesis Laboratory and a Computational Chemistry/Data Science Laboratory. Author of 70 publications in high-impact factor journals and patents, with several academic, corporate, and international awards and recognitions.
Pharmacist, PhD in Pharmaceutical Technology, both by University of São Paulo (USP). Pharmaceutical R&D leader with a track record on translating formulation and analytical development into commercially successful multi-million dollar’s products. Accumulated eighteen years of experience in industry heading teams at top Brazilian and multinational pharmaceutical companies, in addition to academic research, with multiple patents and scientific papers as author. Solid knowledge on many pharmaceutical processes from bench to industrial scale, advanced analytical tools and development of an extensive network throughout the entire sector. Counselor of Supera Park, an ecosystem of innovation and entrepreneurship that integrates universities, research institutes, startups and technology companies.
Mr. Saverio joins Nintx as the Company’s first Advisory Board member
November 2021
Nintx and CNPEM will collaborate on the research of natural products as starting points to develop novel therapies for multifactorial diseases (multi-target therapies)
September 2021
The partnership is leveraged by a flagship project that has the potential to treat a multifactorial disease (multi-target therapy)
September 2021
Nintx and Join Analytics will build a data-driven solution to map medicinal plants as starting points for discovery projects
July 2021
The objective of the event "Innovation in R&D from Biodiversity" is to discuss at length Nintx's purpose of decoding the complex biological interactions (plants/microorganisms) existing in the Brazilian biodiversity into new therapies, as well as the vision, solution, therapeutic areas and approach proposed by the startup
June 2021
The goal of the event is to connect references from large industries that are constantly mindful of sustainable development and preservation of the environment
June 2021
Nintx, Natura, BRF and Bemol join EMERGE AMAZONIA to map sustainable technologies from the local biodiversity that contribute to economic, social and environmental development
May 2021
The Radcliffe Institute for Advanced Study at Harvard University promoted a symposium to catalyze partnerships and new research based on natural products
May 2021
Recent advances in science and technology and their intersection with biological diversity can exponentialize the development of breakthrough therapies
May 2021
